KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent
Clinical trial NCT05001724 · TERMINATED
Trial details
- NCT number
- NCT05001724
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Status
- TERMINATED
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-10-28
- Primary completion
- 2023-02-13
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.